About My Health Careers Internship MedBlogs Contact us

Is Immunotherapy the Cure for Cancer?

Font : A-A+

 Is Immunotherapy the Cure for Cancer?

Cancer immunotherapy is a treatment that involves using certain parts of an individual's immune system to fight cancer.

This can be achieved by stimulating one's own immune system to attack cancer cells or by supplementing the immune system with components, such as man-made immune system proteins.


Over the last few years, immunotherapy has become an important part of treating some types of cancer, but is not yet as widely used as surgery, chemotherapy and radiation therapy. Unlike other cancer therapies that target the tumour directly, immunotherapy works by recruiting immune cells that target the disease instead.

Owing to the immune system's unique properties, immunotherapy for cancer may hold greater potential than the current treatment approaches. It can help fight cancer more effectively, offer long-term protection against the deadly disease, have fewer side effects, and can benefit more patients with more types of cancer.

Normally body cells grow and divide to make new cells, and then die in an orderly way. Cancer starts when cells in a part of the body begin to grow out of control. Cancer cell growth differs from normal cell growth as instead of dying, cancer cells continue to grow and form new and abnormal cells. One reason that cancer cells thrive in the body is because they are able to hide from the immune system.

The immune system is a complex network of cells, tissues, and organs that work together to protect against disease or other potentially damaging foreign bodies. The immune system's ability to detect and destroy abnormal cells may prevent the development of many cancers. However, some cancers are able to evade the immune system.

The cancer cells produce signals that reduce the immune system's ability to detect and kill tumor cells. At the end of a normal immune response, the immune system produces some signal molecules that suppress itself. This is probably what the cancer cells do, to shut off the immune system. They evolve the ability to produce some of the chemicals that would normally dampen the immune response.

Sometimes, the tumor cells may have changes that make it harder for the immune system to recognize and target them. It appears like healthy normal tissue to the immune system, thereby stopping it from being destroyed.

Some truly exciting researches are happening in the field of immunotherapy. Data presented at the American Society of Clinical Oncology (ASCO) meeting revealed that advanced melanoma skin cancers (shrank when two immunotherapy drugs were given in combination. The UK-led research team used a combination of Nivolumab and ipilimumab to treat patients with advanced melanoma.

Nivolumab binds to a molecule on the surface of immune cells called PD-1. PD-1 prevents the destruction of cancer cells by the immune system. By binding with PD-1, nivolumab effectively stops one of the ways cancer cells avoid being destroyed by the immune system. Ipilimumab works in a slightly different way. In simple words, it releases the brakes on the immune system. The dual treatment saw over half (57%) of patients in the study respond to the treatment, as opposed to only a fifth (19%) who were given ipilimumab alone. However, these drugs do not work equally for everyone. Some people do spectacularly well, some show mediocre response, and some do not respond at all. The reason why is still unclear.

Also, immunotherapy is an expensive affair. The research team reported far more severe immunotherapy side effects as a result of the combination of treatments. The associated toxicities were manageable with steroid treatments and no treatment-related death was noted during the study period in the dual therapy group.

Long-term side effects are another major concern of this combination immunotherapy. Researchers are concerned if the change to the immune system could increase the risk of autoimmune diseases. So far the side effects seem to appear only during the treatment period, but long-term follow of patients who responded to immunotherapy has not taken place.

The study has been published in the New England Journal of Medicine.




Source: Medindia

News A-Z
News Category
What's New on Medindia
January is the Thyroid Awareness Month in 2022
Menstrual Disorders
Coffee May Help You Fight Endometrial Cancer
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Immunisation Dealing with Pollen Allergy Immune Checkpoint Inhibitors for Cancer Treatment 

Recommended Reading
Melanoma is a dangerous form of skin cancer caused largely due to exposure to the sun's damaging UV ...
Aspirin Combined With Immunotherapy To Treat Cancer Might Improve Treatment Outcomes
Aspirin suppresses the molecule, prostaglandin E2 (PGE2) that allows tumors to evade the body's ......
Rationale for Use of Targeted Immunotherapy in Sarcomatoid Lung Carcinomas Highlighted
Rare subtypes of poorly differentiated non-small-cell lung carcinomas of high grade and aggressive ....
Immunotherapy Could Stop Resistance to Radiotherapy: Research
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming ...
Dealing with Pollen Allergy
The plants around you that give you sniffles in your nose at specific time of the year are the sourc...
Immune Checkpoint Inhibitors for Cancer Treatment
Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has appro...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)